Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

63.10 -0.65 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,708,686
Open 63.60
Bid (Size) 62.54 (1)
Ask (Size) 64.21 (1)
Prev. Close 63.75
Today's Range 63.08 - 63.73
52wk Range 50.27 - 67.36
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Analyst Expectations For Incyte's Future
Via Benzinga

Performance

YTD
-3.59%
-3.59%
1 Month
+10.22%
+10.22%
3 Month
+11.58%
+11.58%
6 Month
+0.88%
+0.88%
1 Year
+0.25%
+0.25%

More News

Read More
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via Chartmill
9 Analysts Have This To Say About Incyte
Via Benzinga
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
Via Chartmill
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Via Benzinga
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?
Via Benzinga
Topics Economy
Exposures Interest Rates
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
From Incyte Corporation
Via Business Wire
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.